platinum has been researched along with ly2784544 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barak, S; Braisted, JC; Cai, X; Cai, Y; Chan, DW; Chen, CW; Chen, X; Cheung, ANY; Dai, S; Dai, Z; Han, Z; Hao, J; Hao, Q; Huang, X; Kai, Y; Lee, JB; Li, Z; Liu, SS; Meng, Y; Ngan, HYS; Pei, H; Peng, W; Shinn, P; Song, Z; Southall, NT; Sun, W; Tzatsos, A; Xu, Y; Yung, MMH; Zheng, W; Zhou, W; Zhu, W | 1 |
1 other study(ies) available for platinum and ly2784544
| Article | Year |
|---|---|
Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.
Topics: Autocrine Communication; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Immunotherapy; Interleukin-11; Janus Kinase 2; Ovarian Neoplasms; Platinum; Prognosis; Proto-Oncogene Proteins c-fos; Pyrazoles; Pyridazines; Reactive Oxygen Species; Signal Transduction | 2018 |